Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate by Nele Dammeier et al.
CASE REPORT Open Access
Case report of a patient with progressive
multifocal leukoencephalopathy under
treatment with dimethyl fumarate
Nele Dammeier1*, Victoria Schubert1, Till-Karsten Hauser2, Antje Bornemann3 and Felix Bischof1
Abstract
Background: Progressive multifocal leukoencephalopathy is a severe demyelinating disease caused by the polyoma
JC virus in patients with reduced immunocompetence. A few cases of progressive multifocal leukoencephalopathy
have been reported in patients treated with fumaric acid esters.
Case presentation: A 53-year-old Caucasian woman reported to our clinic with a first focal epileptic seizure and mild
cognitive impairment. Since 1.5 years, she was treated with fumaderm for her psoriasis. During that time, her
lymphocyte counts ranged between 450 and 700/μl. Cerebral magnet resonance imaging showed multifocal
subcortical T2 hyperintense lesions with partial gadolinium enhancement. She did not have antibodies against
human immunodeficiency virus 1 and 2 and cerebrospinal fluid-polymerase chain reaction for viral infections
including a sensitive JC-virus polymerase chain reaction were negative. The diagnosis of progressive multifocal
leukoencephalopathy was established by histological analysis and detection of JC-virus desoxyribonucleic acid in
brain biopsy specimens. Dimethyl fumarate was stopped and Mirtazapin and Mefloquin were initiated. Neurological
examination and imaging remained stable.
Conclusions: Progressive multifocal leukoencephalopathy can occur in patients with lymphocyte counts between 450
and 700/μl, produce only faint symptoms and is not excluded by negative JC-virus-polymerase chain reaction in
cerebrospinal fluid. The incidence of progressive multifocal leukoencephalopathy may thus be underestimated
and a more careful surveillance of patients would be necessary.
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Background
Progressive multifocal leukoencephalopathy (PML) is a
severe demyelinating disease of the central nervous sys-
tem (CNS) caused by the polyoma JC virus in patients
with reduced immunocompetence within the CNS. PML
may develop in patients treated with immunomodulatory
treatment such as natalizumab, rituximab, efalizumab,
infliximab or mycophenolat mofetil [1]. Recently, a few
cases of PML in patients with psoriasis treated with fu-
maric acid esters have been reported [2–4]. In one case no
severe lymphopenia was detected as the reported nadir of
lymphocytic count was 792/μl [5]. The active antipsoriatic
agent monomethylfumarate inhibits the expression of
proinflammatory cytokines, tumor necrosis factor alpha,
interleukin-6, interleukin-1 alpha [6] and increases the
secretion of interleukin-4 and interleukin-10 by helper
T-cells [7]. Dimethyl fumarate was also introduced as
an oral drug for relapsing remitting forms of multiples
sclerosis (MS) [8]. Regarding the fact that we are already
facing the problem of inducing PML in MS patients treated
with natalizumab and dimethyl fumarate becoming an
alternative drug in these cases, it is of major interest to
understand more about the risk of developing PML by
fumarate therapy.
Case presentation
A 53-year-old Caucasian woman reported to our clinic
in September 2014 with a first and acute episode of tran-
sient confusion and sensory aphasia and a two days his-
tory of headache. She was on medication for arterial
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hypertension and hypothyroidism. Since May 2013 she
received dimethyl fumarate (Fumaderm®) for the treatment
of psoriasis. The patient only received topical treatment
prior to dimethyl fumarate. Her clinical examination on
admission was unremarkable. Cerebral magnet resonance
imaging (MRI) showed several subcortical T2 hyperintense
and partially contrast-enhancing lesions in the right frontal
and left parietal lobes, which were increased in size on
follow-up MRI two weeks later (Fig. 1).
Cerebrospinal fluid (CSF) protein was slightly elevated
(54 mg/l), cell count and IgG-Index were normal and she
had identical oligoclonal bands in serum and CSF. She did
not have antibodies against (Human immunodeficiency
virus) HIV 1 and 2 and polymerase chain reaction (PCR)
for JC-virus desoxyribonucleic acid (DNA) (University
Tübingen (sensitivity of JC-virus DNA: > 1000 copies) and
University Düsseldorf (sensitivity of JC-virus DNA: > 4
copies/assay [9]), Germany) of CSF was negative. Histo-
logical analysis of a biopsy of the right frontal lesion
showed infiltration of lymphocytes, perivascular CD45-
positive cells, CD68-positive microglia, reactive astrocy-
tosis and focal demyelination (Fig. 2). Some cells had
intranuclear inclusions and stained positive with an
antibody against JC virus. PCR of brain tissue for JCV
DNA was positive and confirmed the diagnosis of PML.
Treatment with dimethyl fumarate was stopped and
she was put on 250 mg Mefloquin per week and 45 mg
Mirtazapin per day. The patients peripheral lymphocyte
counts during treatment with dimethyl fumarate were
retrospectively evaluated (Fig. 3) and ranged between 450
and 700 cells/μl while her leucocyte counts were higher
than 3000/μl during the whole treatment period. The
initial symptoms were considered to be epileptic and
treatment with 1000 mg/day Levetiracetam was initiated.
Upon follow-up three months later, the patient reported
of persistent difficulties with concentration and word re-
trieval. Aphasia could not be detected in simple conversa-
tion and bed side tests. Neurological examination as well
as repeated cerebral MRI showed no evidence for disease
progression or immune reconstitution inflammatory syn-
drome. Upon 7-month follow-up the patient reported a
stable course of disease with unchanged minor difficulties
with concentration and word retrieval, which were very
mild and could not be detected in conversation or neuro-
logical examination. The MRI showed an increase of the
T2 hyperintense lesion in the right frontal lobe, while
Fig. 1 MRI of the patient’s brain in the course of the disease. shows MR imaging of the brain at the onset of symptoms and imaging controls after
two weeks and 3.5 months. Several subcortical lesions are located in the right frontal and left parietal lobe and show progression during the first two
weeks. They present hyperintense lesions in T2/FLAIR with partial increased signal in contrast-enhanced imaging.
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gadolinium enhancement and the other lesions remained
unaltered. The patient tolerated the treatment well and re-
ported no adverse events.
Conclusions
A few cases of PML in patients treated with fumarates
have been reported [3, 10, 11]. This case demonstrates
that clinical examination, imaging of the brain and a
sensitive JCV DNA PCR of CSF may not be sufficient to
establish the diagnosis. There is evidence that an import-
ant risk factor for the development of PML is prolonged
therapy-associated lymphopenia [12]. In these cases, discon-
tinuation of the treatment is inevitable. The recommended
acceptable threshold for therapy-associated lymphopenia is
specific for any given drug. While the dosage of di-
methyl fumarate has to be reduced when lymphocyte
counts are lower than 700/μl, this threshold is 200/μl
for fingolimod. Our patient demonstrates that PML can
occur in patients with lymphocyte counts ranging be-
tween 450 and 700/μl for prolonged time periods. In
another reported case, the lymphocyte nadir was 792/
μl, indicating that no severe lymphopenia is required
for PML to develop [5]. An alteration of immune sur-
veillance for months or years appears to be critical for
the development PML as it is the case in patients treated
with natalizumab or efalizumab [13]. This case further
demonstrates that PML may cause no or only faint symp-
toms and is not excluded by negative sensitive PCR
for JCV DNA. Sensitivity of the assay used in the ref-
erence laboratory in Düsseldorf was 3.9 copies/assay
(117 copies/ml), as they used an amplification protocol
identical to the one used by Ryschekowitsch et al. [9].
As the sensitivity in various laboratories differs it could be
necessary to analyse the CSF in a more sensitive labora-
tory in case of a negative result. Moreover, reactivation of
JCV may not only lead to PML, but also to JCV associated
Fig. 2 Histological analysis of a brain biopsy from the right frontal
lesion. (a) Enlarged nuclei containing viral inclusions (arrows).
Hematoxylin and eosin. (b) Enlarged nuclei appear immunopositive
when labeled with an antibody to JC-virus/SV40.
Fig. 3 Absolute numbers of lymphocytes and dose of fumaric acid. After two months of application the lymphocyte count fell to a level of 700 cells/μl.
At that point treatment was stopped until lymphocyte count recovered to a number of 900/μl after two and a half months. Dimethyl fumarate was given
in an increasing dose up to 360 mg per day. When the symptoms of the psoriasis remained stable, the daily dose was decreased to 240 mg and increased
again when the symptoms remitted. At the same time lymphocytes remained at an average level of about 600/μl. When they first fell under 500 cells/μl in
October 2014, dimethyl fumarate dose was reduced to 120 mg. Finally, the therapy was stopped by the diagnosis of a PML. During the following months
lymphocytes recovered slowly and reaching a number of 3000 – 5000 cells/μl.
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granule cell neuronopathy [4, 14, 15], JCV encephalopathy
[16] or JCV associated meningitis [17].
The incidence of PML in patients with long term immu-
nomodulating or immunosuppressive therapy is thus
possibly currently underestimated and a more careful
surveillance of these patients would be necessary.
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